At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
3 articles- Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseasesGlobeNewswire Biotech·2026-06-19press release
- TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialGlobeNewswire Biotech·2026-06-09press release
- Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi CollaborationGlobeNewswire Biotech·2026-06-09press release
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacogenomic Study, and 3 other interventions for Metastatic Malignant Solid Neoplasm and 4 related conditions. Active but no longer recruiting, targeting 88 participants across 15 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to treatment, or primary peritoneal cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib with chemotherapy may kill more tumor cells.
Study Details
Timeline
Interventions
Correlative studies
Correlative studies
Correlative studies
Given IV
Given PO